Skip to content
TrialScanner

NCT06528483

Bladder Preservation With Sacituzumab Govitecan + Zimberelimab for Muscle-Invasive Bladder Cancer

Phase 2Not yet recruitingGILDCollaborator

Registry record

Lead sponsor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Conditions
Bladder Cancer; Bladder Urothelial Carcinoma; Bladder Neoplasm; Muscle-Invasive Bladder Carcinoma
Primary completion
Dec 31, 2026Sponsor estimate
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Sponsor estimate: the sponsor registered this date in advance and can move it. A primary completion date is when the last participant is measured, not when results are announced.

Open NCT06528483 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT06528483: Bladder Preservation With... | TrialScanner